What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Cancer
Timothy P. Hughes focuses on Imatinib, Imatinib mesylate, Internal medicine, Myeloid leukemia and Leukemia.
His work carried out in the field of Imatinib brings together such families of science as Chronic myelogenous leukemia, Surgery and Tyrosine-kinase inhibitor.
The Imatinib mesylate study combines topics in areas such as Discontinuation, Adverse effect, Pharmacology, Randomized controlled trial and Alpha interferon.
His Internal medicine research is multidisciplinary, relying on both Gastroenterology, Immunology and Oncology.
The study incorporates disciplines such as Clinical trial, Hypophosphatemia, Intensive care medicine, CRKL and Disease in addition to Myeloid leukemia.
His research in Leukemia intersects with topics in Myeloid, Targeted therapy, Molecular Response and Stem cell.
His most cited work include:
- Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia (2888 citations)
- Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia (2837 citations)
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 (1271 citations)
What are the main themes of his work throughout his whole career to date?
Timothy P. Hughes mainly focuses on Internal medicine, Imatinib, Imatinib mesylate, Myeloid leukemia and Nilotinib.
His Internal medicine study integrates concerns from other disciplines, such as Immunology, Gastroenterology and Oncology.
His Imatinib research integrates issues from Chronic myelogenous leukemia, Pharmacology and Tyrosine-kinase inhibitor.
His study in Imatinib mesylate is interdisciplinary in nature, drawing from both Neutropenia, Surgery, Philadelphia chromosome and Cohort.
As part of one scientific family, Timothy P. Hughes deals mainly with the area of Myeloid leukemia, narrowing it down to issues related to the Leukemia, and often Myeloid.
Timothy P. Hughes combines subjects such as Newly diagnosed, Adverse effect, Discontinuation and Clinical trial with his study of Nilotinib.
He most often published in these fields:
- Internal medicine (61.33%)
- Imatinib (56.58%)
- Imatinib mesylate (36.91%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (61.33%)
- Myeloid leukemia (35.41%)
- Oncology (30.66%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Myeloid leukemia, Oncology, Cancer research and Nilotinib.
His studies in Myeloid leukemia integrate themes in fields like Leukemia, Phases of clinical research and Tyrosine-kinase inhibitor.
His Oncology research includes elements of Toxicity and Cohort.
His work deals with themes such as Mutation, Gene, Intron, Tyrosine kinase and RNA splicing, which intersect with Cancer research.
His Nilotinib study is related to the wider topic of Imatinib.
His Imatinib mesylate research incorporates elements of Neutropenia and Intention-to-treat analysis.
Between 2017 and 2021, his most popular works were:
- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia (160 citations)
- Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial (143 citations)
- Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study. (66 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Cancer
Timothy P. Hughes spends much of his time researching Myeloid leukemia, Internal medicine, Imatinib, Nilotinib and Leukemia.
Many of his research projects under Myeloid leukemia are closely connected to In patient with In patient, tying the diverse disciplines of science together.
His Internal medicine study integrates concerns from other disciplines, such as Philadelphia chromosome and Oncology.
He works mostly in the field of Imatinib, limiting it down to topics relating to Discontinuation and, in certain cases, Bosutinib and European LeukemiaNet.
His Nilotinib research is multidisciplinary, relying on both Adverse effect and Dasatinib.
His study in Leukemia is interdisciplinary in nature, drawing from both Neoplasm and Molecular Response.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
